GLP‐1 and cardiovascular disease in diabetes

E-ISSN： 1476-5381|172|3|721-736

ISSN： 0007-1188

Source： BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol.172, Iss.3, 2015-02, pp. : 721-736

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Liraglutide: a human GLP-1 analog for Type 2 diabetes

By Vilsbøøll Tina

Therapy, Vol. 6, Iss. 2, 2009-03 ,pp. : 199-207

Future Medicine

Access to resources Recommend Favorite

Dulaglutide: a once‐weekly GLP‐1 for type 2 diabetes

PRESCRIBER, Vol. 26, Iss. 19, 2015-10 ,pp. : 28-30

John Wiley & Sons Inc

Access to resources Recommend Favorite

Diabetes and cardiovascular disease: time for individualized risk reduction

By McFarlane Samy I Sowers James R

Therapy, Vol. 6, Iss. 4, 2009-07 ,pp. : 451-453

Future Medicine

Access to resources Recommend Favorite

Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes

By Ross Stuart A. Ballantine Jane

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1617-1626

Informa Healthcare

Access to resources Recommend Favorite

Current treatments and strategies for type 2 diabetes: Can we do better with GLP-1 receptor agonists?

By Peterson Gregory

Annals of Medicine, Vol. 44, Iss. 4, 2012-06 ,pp. : 338-349

Informa Healthcare

Access to resources Recommend Favorite